anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as a sterile solution for intravenous use in INTRAVIA plastic containers.

Fluconazole is designated chemically as 2,4-difluoro-α,α1-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl alcohol with an empirical formula of C13H12F2N6O and molecular weight of 306.3. The structural formula is:

Fluconazole is a white crystalline solid which is slightly soluble in water and saline.

Fluconazole in Sodium Chloride Injection, USP is an iso-osmotic, sterile, nonpyrogenic solution of fluconazole in a sodium chloride diluent. Each mL contains 2 mg of fluconazole and 9 mg of sodium chloride. The pH ranges from 4.0 to 6.5 in the sodium chloride diluent. Injection volumes of 100 mL and 200 mL are packaged in INTRAVIA plastic containers.

The flexible container is manufactured from a specially designed multilayer plastic (PL 2408). Solutions in contact with the plastic container can leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. The flexible container has a foil overwrap. Water can permeate the plastic into the overwrap, but the amount is insufficient to significantly affect the premixed solution.

Fluconazole in Sodium Chloride Injection, USP meets USP Organic Impurities Procedure 3.
BACKGROUND: Gram-negative bacteria resistant to carbapenems are also known as critical antimicrobial resistant organisms. Their emergence at Colonial War Memorial Hospital (CWMH), the largest hospital in Fiji, is a major clinical concern. This study was conducted to determine the knowledge, attitudes, and readiness of healthcare workers (HCW) at CWMH regarding management of patients with infections caused by critical antimicrobial resistant organisms.
METHODS: A questionnaire was designed using a Likert scale to assess knowledge, attitudes, and readiness. Two cross-sectional studies were conducted, before and after the implementation of targeted educational activities which were informed by the pre-intervention study findings.
RESULTS: A total of 393 and 420 HCW participated in the pre- and post-intervention studies, respectively. The majority of respondents were female (77.3%) and 18-34 years of age (67%). HCW professional roles included nurses (56.3%), doctors (31.6%), and laboratory personnel (12.2%). In the post-intervention study, significantly more HCW reported having received infection prevention and control (IPC) and antimicrobial resistance education and training (26.8% in pre to 45.5% in post intervention, p < 0.001). The majority of nurses and doctors (> 85% to ≥ 95%) were aware of how AMR organisms spread in healthcare settings and knew the IPC measures to prevent transmission of AMR infections including hand hygiene, standard and transmission-based precautions. Attitudes towards AMR were positive, with 84.2% pre intervention and 84.8% of HCW post intervention expressing their willingness to change their work environment to assist with AMR prevention. Perceived readiness to address the problem showed mixed results. Improvements in laboratory AMR surveillance data availability were noted (29.4-52.4%, p < 0001). Modest improvement in the hospital's capacity for outbreak response (44-51.9%, p = 0.01), and treatment of AMR infections (38.9-44.4%, p = 0.01) was reported.
CONCLUSIONS: Our data revealed high levels of staff awareness and knowledge about AMR and IPC. However, readiness for outbreak response and treatment of critical AMR infections requires more attention. Improving AMR prevention and containment in CWMH will likely require sustained and multisectoral interventions with strong administrative commitment.
The hypoglycemia or hyperglycemia which occurs during octreotide acetate injection therapy is usually mild, but may result in overt diabetes mellitus or necessitate dose changes in insulin or other hypoglycemic agents. Hypoglycemia and hyperglycemia occurred on octreotide acetate injection in 3% and 16% of acromegalic patients, respectively. Severe hyperglycemia, subsequent pneumonia, and death following initiation of octreotide acetate injection therapy was reported in one patient with no history of hyperglycemia.

In patients with concomitant Type I diabetes mellitus, octreotide acetate injection may affect glucose regulation, and insulin requirements may be reduced. Symptomatic hypoglycemia, which may be severe, has been reported in these patients. In nondiabetics and Type II diabetics with partially intact insulin reserves, octreotide acetate injection administration may result in decreases in plasma insulin levels and hyperglycemia. It is therefore recommended that glucose tolerance and antidiabetic treatment be periodically monitored during therapy with these drugs.
The subjects in this group will receive 3 times per week, and 4 weeks of continuous intervention for a total of 12 times. The intervention including sham electroacupuncture(sham EA) intervention and combined with carbamazepine. The follow-up period is 6 months.
The invention relates to a preparation method and a use of biocompatible temperature-sensitive gel microspheres. The biocompatible temperature-sensitive gel microsphere comprises a, 1-10wt% of 12-hydroxy stearic acid (HSA) and b, 90-99wt% of plant oil, wherein preferably, the plant oil is edible oil such as soybean oil and peanut oil. The biocompatible temperature-sensitive gel microspheres can load a plurality of substances, can control release of the substances, has good temperature sensitivity at a temperature of 30-70 DEG C, has different phase-transition temperatures, and can satisfy different temperature control demands. The preparation method can adjust reaction conditions according to different demands and prepare microspheres with different particle sizes. The biocompatible temperature-sensitive gel microsphere has good mechanical properties and thermodynamic properties, can bear a certain shearing force and pressure, can retain a stable shape and functions for a long time, contains main ingredients of HAS and plant oil extracted from plants and does not produce toxicity and damage to organisms and environment. The ultrasonic emulsification preparation process has simple processes, is free of other stabilizing agents and has a low cost. The biocompatible temperature-sensitive gel microspheres can be widely used in the field of drug slow release, pesticide slow release, food embedding and anticorrosion paint.
Rheumatoid Arthritis (RA) is a chronic inflammatory arthritis of substantial morbidity. Serum biomarkers such as Rheumatoid Factor and anti-cyclic citrullinated peptide assist with disease diagnosis and prognostic assessment of future disease activity. 14-3-3 eta is a relatively new RA serum biomarker. The 14-3-3 family of proteins were named based on chromatographic elution properites and are ubiquitously expressed intracellular chaperon proteins. The isoform relevant in RA is 14-3-3 eta. 14-3-3 eta provides additional information about RA to the clinician-it assists in making diagnosis, provides prognostic assessment of disease severity, and provides insight regarding response to therapy. Thus, 14-3-3 eta serves as an important mechanistic biomarker informing the clinician about patient's RA.

14-3-3 eta is the product of the YWHAH gene, located on chromosome 22q12.3. It is about 13 kilobase long, consisting of two exons separated by a single intron. This gene has been implicated in linkage studies to bipolar disorder and schizophrenia. Six YWHAH single nucleotide polymorphisms (SNPs) were identified in a prior study: rs2246704, rs2853884, rs3747158, rs4820059, rs7291050, and rs933226. rs2246704 was associated with bipolar disorder (Odds Ratio (OR) 1.31, p=0.03) and psychotic BP (OR 1.66, p=0.002). All six SNPs are intronic. It was hypothesized that one or several of these 6 single nucleotide polymorphisms (SNPs) could be related to RA disease severity.
in this study 300 postmenopausual women will be selected suffering from stress unrinary incontinence. Their age ranges from 60 to 70 years old. Their BMI is not exceeding 30 kg/m2. different methods of assessment will be used as : Data recording sheet, Weight-Height scale, Goniometer ,x ray radiography ,Transabdominal ultrasound and Perineal ultrasound. Data recording sheet: It will be used to record data of each woman before starting this study. Weight-Height scale: It will be used to measure weight and height of each woman before starting this study. Goniometer: it will be used to document the initial and the subsequent range of motion for ankle joint for each woman. Transabdominal ultrasound: it will be used for measurement of Post-void residual volume PVR for each woman which is the volume of urine left in the bladder after micturition . Perineal ultrasound: it will be used to assess the posterior urethrovesical angle for each woman . X-ray radiography: lateral pelvic radiographs will be taken for each woman in order to objectify the individual pelvic tilt. Inclusion criteria include : Subjects will be postmenopausal women complaining from stress urinary incontinence Participants age will range from 60-70 years.Their BMI will not exceed 30 kg/m2. Exclusion criteria: previous history of cancer and radiotherapy, any disease that could interfere with the participation, lower urinary tract infections( Manshadi F. etal ) musculoskeletal problems; previous major abdominal or pelvic surgery; severe diseases; diabetes mellitus, a body mass index \>30 kg/m2; intraureterine device implantation, pelvic organ prolapse and menopause (Cerruto M etal.)
The CC intervention will consist of offering subjects: 1) an in-depth baseline assessment, 2) frequent (weekly first, then monthly) visits with a nurse care manager, 3) alcohol dependence medications prescribed by a Nurse Practitioner. An interdisciplinary CC team will supervise nurse care managers weekly.
This study will enroll patients scheduled to receive radiation therapy (RT), but RT details are not specified by this protocol. Patients taking long acting opioid analgesics prior to enrollment will be converted to an equivalent dose of Xtampza ER at the time of enrollment. For the remaining patients not previously prescribed opioid analgesics, Xtampza ER will be initiated when 2 or more daily doses of short acting opioids are required, resulting in a total daily dose of at least 30mg morphine sulfate equivalent. During RT, pain will be assessed on a weekly basis using the PI-NRS and the dose of Xtampza ER will be adjusted at the discretion of the treating physician, with recommendation to maintain an equivalent of 100% daily opioid requirement. Assessment for tapering of Xtampza ER will begin 1 month following the completion of RT at the time of first follow-up.The study period will end 3 months following the final fraction of RT.
Starting at Day 1 of the Randomized Evaluation Period, participants will receive asfotase alfa for a total of 24 weeks. Participants will receive 6 mg/kg/week of asfotase alfa via SC injection as either 2 mg/kg 3 times per week or 1 mg/kg 6 times per week. Part A of the OLE Period participants will have frequent visits over the first 24 weeks; Part B will have visits every 9 months for up to approximately 108 weeks.
Participants will receive the online Sleepio intervention to be completed approximately once per week, at least 6 sessions during the 8-week period, and complete daily sleep diaries. In addition they will continue their treatment as usual (TAU) with the CAMEO Early Intervention in Psychosis CPFT or Early Intervention in Psychosis Services NSFT care team.
Patients receive Hsp90 inhibitor STA-9090 IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
OBJECTIVE: To explore the impact of diabetes on collateral circulation (CC) development in patients with chronic total coronary occlusion (CTO) and the underlying regulatory mechanism.
METHODS: This study was conducted among 87 patients with coronary heart disease (CHD), who had CTO in at least one vessel as confirmed by coronary angiography. Among them 42 patients were found to have a low CC level (Cohen-Rentrop grades 0-1) and 45 had a high CC level (grades 2-3). In the 39 patients with comorbid diabetes mellitus and 48 non-diabetic patients, insulin resistance (IR) levels were compared between the subgroups with different CC levels. The steady-state mode evaluation method was employed for calculating the homeostatic model assessment for insulin resistance index (HOMA-IR) using a mathematical model. During the interventional procedures, collateral and peripheral blood samples were collected from 22 patients for comparison of the metabolites using non-targeted metabolomics analysis.
RESULTS: NT-proBNP levels and LVEF differed significantly between the patients with different CC levels (P<0.05). In non-diabetic patients, HOMA-IR was higher in low CC level group than in high CC level groups. Compared with the non-diabetic patients, the diabetic patients showed 63 upregulated and 48 downregulated metabolites in the collateral blood and 23 upregulated and 14 downregulated metabolites in the peripheral blood. The differential metabolites in the collateral blood were involved in aromatic compound degradation, fatty acid biosynthesis, and steroid degradation pathways; those in the peripheral blood were related with pentose phosphate metabolism, bacterial chemotaxis, hexanoyl-CoA degradation, glycerophospholipid metabolism, and lysine degradation pathways.
CONCLUSION: The non-diabetic patients with a low level of CC had significant insulin resistance. The degradation pathways of aromatic compounds, fatty acid biosynthesis, and steroid degradation are closely correlated with the development of CC.
Methaemoglobin (metHb) possesses inherent characteristics that facilitate reversible binding to hydrogen sulphide. Exogenous hydrogen sulphide supplementation imparts beneficial bioactive effects, including antioxidant and anti-inflammatory; hence, we hypothesized that the metHb-hydrogen sulphide complex could act as a hydrogen sulphide donor for medication. In this study, we prepared a hydrosulphide-metHb-albumin (H2S-metHb-albumin) cluster and examined its applicability as a hydrogen sulphide donor in the mice model of hepatic ischemia-reperfusion injury. Structural analysis revealed that the H2S-metHb-albumin cluster exhibited a nanostructure wherein one metHb was wrapped by an average of three albumins, and hydrogen sulphide was bound to the haem. Additionally, the H2S-metHb-albumin cluster exhibited low-pH responsiveness, leading to sustained release of hydrogen sulphide. Owing to these structural and pharmaceutical characteristics, the severity of hepatic ischemia-reperfusion injury was alleviated via antioxidant and anti-inflammatory effects of the H2S-metHb-albumin cluster treatment. The protective effects were more potent in the H2S-metHb-albumin cluster compared to that in a conventional hydrogen sulphide donor (sodium hydrogen sulphide). No abnormal signs of toxic and biological responses were observed after the H2S-metHb-albumin cluster administration, confirming high biological compatibility. These results successfully establish the proof of concept that the H2S-metHb-albumin cluster is a promising hydrogen sulphide donor. To the best of our knowledge, this is the first report demonstrating the remarkable potential of metHb as a biomaterial for hydrogen sulphide donors.
A method and apparatus for examining data from a chemical analyzer for artifactual results. A set of rules are established to identify artifactual results based upon experience with the analyzer. Moreover, each rule can be associated with a sample collection or testing problem which potentially caused the artifactual result. Using these rules, output data from the analyzer can be tested to see if any of the rules are satisfied. If a rule is satisfied, then an artifactual result can be indicated, as well as the potential cause of the artifactual result. An output file can be created which indicates the artifactual data samples and the potential artifactual causes. Preferably, the rules are provided in a user-modifiable data file, so that the rules may be modified based upon additional experience. The rules file and output file are also preferably provided in a user-friendly format, such as in a spreadsheet or database application format for example.
The invention belongs to the field of medicinal preparation and discloses an oleanolic acid osmotic pump tablet and a preparation method thereof. The oleanolic acid osmotic pump tablet comprises three parts, namely, a medicine-containing layer, a boosting layer and a coating layer, and is prepared by adopting a single punch tablet press and a two-time filling and two-time pressurizing method to press and prepare two-layer tablet core, and opening a medicine-releasing hole on the surface of one side of the medicine-containing layer. The medicine-containing layer comprises a main medicine, a suspending agent, a binding agent, a penetrating agent, an osmotic pressure active substance, a lubricating agent and the like. The boosting layer comprises a high-molecular swelling agent, the osmotic pressure active substance, the binding agent, the lubricating agent and the like. The coating layer mainly comprises a film-forming material, a plasticizer, a hole-forming agent and the like. In the invention, the preparation takes zero-order release dynamics as a characteristic, the medicine is released constantly, the concentrations of the blood and the medicine are stable, the effective time is long and the purpose of releasing the medicine in 24 hours, i.e. taking the medicine once everyday is achieved.
This invention concerns a method for sealing dentinal tubules exposed at the tooth surface as a consequence of enamel defects, based on amorphous calcium polyphosphate microparticles that, in contrast to polyphosphate-calcium salts/complexes, strongly bind both to tooth enamel, cementum and dentin surfaces. The inventive method uses microsized particles, consisting a biocompatible and biodegradable polymer (calcium polyphosphate), can be applied not only for protective teeth coatings but also in the fabrication of morphogenetically- active tooth implants that stimulate differentiation of precursor odontoblasts to mature, alkaline phosphatase-expressing cells, with a hardness and elastic modulus close to natural enamel. The invention furthermore relates to an improved biomimetic dental composition, in particular a toothpaste, containing the morphogenetically active amorphous polyphosphate (polyP) microparticles enriched with retinyl acetate. The inventive composition efficiently repairs both cracks/fissures and carious lesions in the tooth enamel, and reseals dentinal tubules, already after a short-time treatment of teeth. Moreover, this composition significantly increases the growth of human mesenchymal stem cells and the expression of marker genes for osteoblast differentiation. A further aspect of this invention then concerns the finding that the polyP ingredient, supplied as zinc-polyP microparticles strongly inhibits the growth of the cariogenic bacterium  Streptococcus mutans . The inventive composition is particularly suitable for a prevention/repair of (cariogenic) damages of tooth enamel/dentin and for the treatment and/or prevention of dental hypersensitivity.
This was a retrospective study that aimed to provide a first estimate of the prevalence of developmental language disorder (DLD) in Mexico, where there is currently a lack of epidemiological data on this disorder. Children aged 4;0 to 6;11 years in the cities of Mexico, Queretaro, and Monterrey were classified into two groups: those with DLD (N = 46) and those with typical language development (N = 497). The diagnosis of DLD was based on standardized norm-referenced assessment and language sample analyses. Children with other disabilities were excluded from the final sample. The final sample consisted of 543 children (55% male; 45% female) aged 4;0 to 6;11 years. The estimated prevalence of DLD was 8.5%. The study has clinical implications given that the prevalence of DLD in Mexico may raise awareness of this long-lasting disorder and may help health and educational authorities establish a system to early identify and diagnose children with DLD.
PURPOSE:To obtain a raw material for cosmetic, giving mild feeling to skin, having massaging effect and capable of mitigating the action of pH, by pulverizing of deashing shell or pearl of a shellfish having nacreous layer, finely pulverizing the produced conchiolin and, if necessary, bleaching the product. CONSTITUTION:Shell and/or pearl of a shellfish having nacreous layer (e.g. Japanese pearl oyster, hard-shelled mussel, etc.) are finely pulverized or deashed with an acid to obtain conchiolin, which is finely pulverized and optionally bleached to form the objective raw material for cosmetic. The cosmetic raw material is composed mainly of protein-based organic fine powder having low hardness and mild action to skin. Accordingly, the material has extremely low irritation and gives massaging effect to skin. The action of pH can be remarkably mitigated by compounding conchiolin to cosmetic cream or face powder and the material is suitable for a carrier to retain a drug, perfume, pigment, etc. The present invention is also worthwhile as an effective utilization method of hitherto disposed shell and pearl scrap.
Policy of routine use of fibrinolysis inhibitors 4 hours after surgery. Patients in this group will receive 70% of the routine prophylactic dose of fibrinolysis inhibitor administered by the center during surgery. Additionally, they will receive 30% of the dose as an IV infusion within 4 hours after the surgery.
FIELD: medicine; pharmaceuticals.SUBSTANCE: invention refers to pharmaceutical industry. Disclosed is a method of producing a composition for inhibiting activity β-glucuronidase, according to which a phosphate buffer solution of a copolymer of vinyl pyrrolidone and vinyl amine (containing 90 mol. % vinyl pyrrolidone units and 10 mol. % vinyl amine units) with concentration thereof in solution of 10–12 wt. %, preparing a phosphate buffer solution of mixture of 1,4- and 3,6-lactones of D-sugar acid with ratio of 40–60/60–40 wt. % with concentration in solution of 21.5–24.0 wt. %, then obtained solutions are mixed, then combined solution is treated with 25 % sodium hydroxide solution to pH equal to 4.8–4.9, at 20–25 °C and lyophilic drying said solution.EFFECT: invention provides higher inhibition efficiency β-glucuronidase with prolonged action of obtained composition.1 cl, 4 ex, 2 tbl
Subjects who are randomised to Intervention Arm will be taking a drink containing 25g of Sarawak sago starch in 200mL of plain water. The subjects will take the drink twice daily i.e., within 30 minutes before lunch and dinner. On top of that, they will be counselled on diet recommendations for diabetes by a study dietitian at Visit 1 or baseline.